Open access
Jul 2026
Immunological targeting of the endogenous retroviral protein ERVMER34-1 in carcinomas promotes epitope spread and enhances response to PD-L1 blockade 2306293
The clinical development of a therapeutic cancer vaccine targeting the retroviral envelope protein ERVMER34-1 is supported, which would represent a new class of therapeutic cancer vaccine targeting ERVs.
D. Hamilton, Maria del Mar Maldonado, Renee N. Donahue et al.
· Journal of Immunology · 0 citations